Sectors

PFE
Pfizer Inc.
24.25
1 x 24.23
1 x 24.35
bid
ask
-
0.23
0.94%
1 @ 07:01 PM
24.26 +0.01 (0.04%)
Ytd-2.61%
1y-4.34%
24.14
day range
24.43
23.11
52 week range
28.75
Open24.37Prev Close24.48Low24.14High24.43Mkt Cap137.76B
Vol40.84MAvg Vol40.25MEPS1.31P/E18.45Forward P/E8.53
Beta0.31Short Ratio3.45Inst. Own69.46%Dividend1.72Div Yield7.12
Ex Div Date07-24Earning08-0450-d Avg25.44200-d Avg25.871yr Est28.94
Earning
DateForEstimateReportedSurprisesurprise %
2026-05-052026-030.710.750.045.63%
2026-02-032025-120.570.660.0915.79%
2025-11-042025-090.660.870.2131.82%
2025-08-052025-060.580.780.234.48%
2025-04-292025-030.640.920.2843.75%
2025-02-042024-120.480.630.1531.25%
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-10B of A SecuritiesUpgradeNeutralNeutral
2026-07-08JP MorganUpgradeNeutralNeutral
2026-07-06Cantor FitzgeraldUpgradeNeutralNeutral
2026-07-06HSBCDowngradeBuyHold
2026-06-10RBC CapitalUpgradeUnderperformSector Perform
2026-04-29CitigroupUpgradeNeutralNeutral
Profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Holder
DateNameRelationQuantityDescription
2025-02-12BLAYLOCK RONALD EDirector32.46KPurchase
2026-02-24BOSHOFF CHRISTOFFELOfficer162.09KStock Award(Grant)
2026-02-24BOURLA ALBERTChief Executive Officer394.67KConversion of Exercise of derivative security
2026-06-08DAMICO JENNIFER B.Officer31.40KSale
2026-02-24FONSECA LIDIA PH.D.Officer46.46KConversion of Exercise of derivative security
2024-10-29GOTTLIEB SCOTTDirector10.00KPurchase
Institution Ownership
Report DateOrganizationPositionValuePercentage
2025-12-30Vanguard Group Inc541.35M0.009.50%
2026-03-30BlackRock Inc498.26M0.008.74%
2026-03-30Vanguard Capital Management, LLC369.43M0.006.48%
2026-03-30State Street Corp301.59M0.005.29%
2026-03-30Geode Capital Management, LLC133.56M0.002.34%
2026-03-30Vanguard Portfolio Management, LLC116.73M0.002.05%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-04-29Vanguard Total Stock Mkt Idx Inv181.18M0.003.18%
2026-04-29Vanguard 500 Index Investor147.43M0.002.59%
2026-05-28iShares Core S&P 500 ETF74.91M0.001.31%
2026-04-29Fidelity 500 Index72.86M0.001.28%
2026-05-30State Street® SPDR® S&P 500® ETF68.52M0.001.20%
2026-04-29Vanguard Value Index Inv52.70M0.000.92%
Dividend
DividendDate
0.432026-07-24
0.432026-05-08
0.432026-01-23
0.432025-11-07
0.432025-07-25
0.432025-05-09
Split
SplitDate
1054 : 10002020-11-17
3 : 11999-07-01
2 : 11997-07-01
2 : 11995-07-03
2 : 11991-04-01
2 : 11983-07-01